Estratégias de instituições da sociedade civil no acesso a medicamentos para câncer de mama no SUS

Deprá, Aline Scaramussa; Ribeiro, Carlos Dimas Martins; Maksud, Ivia

doi:10.1590/0102-311x00203413

Cited by 5 publications

(5 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, access to this drug must be appropriately given. Studies report difficulties experienced by users of the Brazilian Unified Health System with breast cancer if accessing chemotherapy treatments already incorporated in the public network [20][21][22][23]33 .…”

Section: Discussionmentioning

confidence: 99%

“…The current literature has clarified several essential aspects of the disease, such as the sweeping panorama of metastatic breast cancer in Brazil and worldwide, patient access to currently available technologies, and previous studies of MCDA in the Health Technology Assessment (HTA) area 8,11,[14][15][16][17][18][19][20][21][22][23]…”

Section: Research Problem Characterizationmentioning

confidence: 99%

See 1 more Smart Citation

Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer

et al. 2023

View full text Add to dashboard Cite

Background The many combinations of chemotherapeutic agents and biologicals available in the Brazilian National Health System for the treatment of metastatic breast cancer require analysis that contribute to decision making. Objective The study’s primary aim was to evaluate the first-line treatment of HER2- overexpressing metastatic breast cancer from the Brazilian Unified Health System perspective using multicriteria decision analysis (MCDA). Method The treatment options evaluated were (a) pertuzumab combined with trastuzumab and docetaxel, and (b) trastuzumab in combination with docetaxel. Using the hierarchical analytical method, medical oncologists compared the relevance of five predefined criteria: overall survival, response to treatment, adverse events, cost- effectiveness, and budget impact. Results The therapeutic scheme considered more appropriate by the model was pertuzumab combined with trastuzumab and docetaxel. The most sensitive criteria were adverse events, cost-effectiveness, and budget impact. The results suggest that the classification has a close relationship with the perspective of healthcare professionals participating in the questionnaire. Conclusion Defining the treatment of an incurable disease associated with a short survival time and high-cost treatment options necessitates complex decision-making. MCDA allows the weighting of criteria and considering criteria that would be difficult to measure in other methods, such as cost-effectiveness. These aspects differ from economic models and contribute to a broader evaluation of health decision-making.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Research Problem Characterizationmentioning

confidence: 99%

Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…As preocupações são claras: o dispendioso investimento, que paradoxalmente reflete em desassistência de diversos usuários do SUS 23 , e a não integralidade do cuidado à pessoa com câncer 11,24 .…”

Section: Dimensão Judicialunclassified

“…As relações duvidosas estabelecidas na impetração de demandas judiciais em oncologia vêm sendo analisadas em outros estudos, que elucidam interesses particulares em detrimento dos coletivos 24,26,27 . Institucionalizar esse tipo de prática pode ampliar iniquidades, propiciando maiores dificuldades para o sistema responder adequadamente às necessidades de saúde da população.…”

Section: Aqui é Assim O Hospital Me Dá Total Autonomia Para Eu Solici...unclassified

Estratégias adotadas para a garantia dos direitos da pessoa com câncer no âmbito Sistema Único de Saúde (SUS)

Silva

Osório-de-Castro

2022

Ciênc. saúde coletiva

View full text Add to dashboard Cite

Resumo Este estudo, fundamentado na Teoria da Estruturação de Giddens, buscou analisar as estratégias adotadas para garantir os direitos das pessoas com câncer em cinco municípios brasileiros, a partir da experiência de gestores e profissionais de saúde no contexto do Sistema Único de Saúde. Foi conduzido um estudo de casos múltiplos. A unidade de análise foi o município e a subunidade foi a unidade habilitada de atenção oncológica. Foi realizada a análise de conduta estratégica de dez gestores e 15 profissionais de saúde, a partir de entrevistas. Os resultados foram sistematizados em três dimensões: assistencial, judicial e social. Destacaram-se: a necessidade de expansão e organização da rede assistencial diagnóstica e terapêutica; a preocupação com o grande número de demandas judiciais, tanto pela sustentabilidade econômica do sistema de saúde, quanto pela promoção de iniquidades; a pouca resolutividade dos benefícios sociais, uma vez que não atendem a todos aqueles que necessitam. A percepção é de que as medidas adotadas são insuficientes para garantir os direitos da pessoa com câncer no sistema de saúde brasileiro.

show abstract

“…Efforts to prioritise the creation of a national cancer programme during the 1990s also benefited from several NGOs throughout Brazil (Perez et al, 2014). In addition, work by Deprá et al (2015) revealed that civil society took advantage of a partnership with the executive branch and presence within national representative institutions, such as the Conselho Nacional de Saúde (CNS) (National Health Council) and the MoH's CONITEC (Commisão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde [National Committee for Health Technology Incorporation]), which focuses on health technology assessment, to inform the public, monitor policies, and exert pressure on the executive branch for access to breast cancer medicine via SUS.…”

Section: Brazilmentioning

confidence: 99%

Institutions, Policy, and Non-Communicable Diseases (NCDs) in Latin America

Gómez

Méndez

2021

Journal of Politics in Latin America

View full text Add to dashboard Cite

Research has underscored the agenda-setting and policy implementation advantages associated with the concentration of political and policy-making authority. But to what extent does this concentration of authority within health policy-making institutions determine the early timing and depth of non-communicable disease (NCD) policies? Are other factors within and outside of government more important? Comparing one Latin American country exhibiting a strong concentration of political and policy-making authority, Mexico, to one that does not, Brazil, we find that weaker, fragmented political and policy-making powers in Brazil expedited the creation and implementation of NCD programs. As seen in Brazil, our findings suggest that the factors that account for the earlier adoption of NCD policies and successful implementation are the early institutionalisation of societal interests and pressures within the bureaucracy, the “bottom-up” diffusion of early policy ideas, and international policy recommendations. This institutional, participatory, and ideational approach may provide more important predictors for explaining variation in NCD policies.

show abstract

Estratégias de instituições da sociedade civil no acesso a medicamentos para câncer de mama no SUS

Cited by 5 publications

References 13 publications

Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer

Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer

Estratégias adotadas para a garantia dos direitos da pessoa com câncer no âmbito Sistema Único de Saúde (SUS)

Institutions, Policy, and Non-Communicable Diseases (NCDs) in Latin America

Contact Info

Product

Resources

About